Terminated × Carcinoma, Non-Small-Cell Lung × Nivolumab × Clear all Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer
Phase 3 Terminated
102 enrolled
Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer
Phase 2 Terminated
14 enrolled 16 charts
Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC
Phase 2 Terminated
5 enrolled 13 charts
ATLAS
Phase 2 Terminated
5 enrolled
Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC
Phase 2 Terminated
6 enrolled 7 charts
A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
Phase 1/2 Terminated
175 enrolled
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
Phase 1 Terminated
221 enrolled
Induction Chemo-Nivo in Unresectable Stage III NSCLC
Phase 2 Terminated
1 enrolled
A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer
Phase 1/2 Terminated
36 enrolled 26 charts
SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation
Phase 1 Terminated
21 enrolled
Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types
Phase 1 Terminated
15 enrolled
Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations
Phase 2 Terminated
19 enrolled 16 charts
Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer
Phase 1 Terminated
17 enrolled
Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer
Phase 2 Terminated
161 enrolled 15 charts
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Phase 1 Terminated
5 enrolled
Phase I Multicenter Trial Combining Nivolumab, Ipilimumab and Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer Patients
Phase 1 Terminated
6 enrolled
Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)
Phase 1/2 Terminated
118 enrolled 18 charts
Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease
Phase 1 Terminated
7 enrolled
Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)
Phase 1/2 Terminated
19 enrolled 12 charts
A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors
Phase 1 Terminated
41 enrolled 24 charts
A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer
Phase 2 Terminated
7 enrolled 9 charts
Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILsâ„¢ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC
Phase 2 Terminated
19 enrolled
Neoadjuvant Immunotherapy in Brain Metastases
Phase 2 Terminated
1 enrolled 7 charts
Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer
Phase 2 Terminated
21 enrolled 12 charts
Study of Nivolumab Verses Nivolumab and Ipilimumab Combination in EGFR Mutant Non-small Cell Lung Cancer
Phase 2 Terminated
31 enrolled
Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer
Phase 2 Terminated
64 enrolled 28 charts
A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)
Phase 1/2 Terminated
11 enrolled 12 charts
Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC
Phase 3 Terminated
20 enrolled 14 charts
Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy
Phase 2 Terminated
3 enrolled 8 charts
Cypress 2
Phase 2 Terminated
52 enrolled 15 charts
Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For Metastatic Disease
Phase 2 Terminated
10 enrolled 8 charts
Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer
Phase 3 Terminated
2 enrolled 6 charts
Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer
Phase 1/2 Terminated
5 enrolled 8 charts
NivoPlus
Phase 1/2 Terminated
33 enrolled